Novartis names Gilbert Ghostine as Chairman designate of Sandoz Board of Directors

Gilbert Ghostine will become Chairman of the New Board of Directors of Sandoz, which will be formed following the spin-off from Novartis in the second half of 2023, subject to final Novartis Board of Directors and shareholder approvals.

“I am excited to join Sandoz, the global market leader in off-patent medicines, as it prepares to spin off from Novartis. Listing Sandoz on the Zurich stock exchange would bring back a Swiss heritage company and an iconic brand in global healthcare. I am greatly looking forward to support Sandoz in its quest to further develop its business as the leading and most valued company in its space”, said  Ghostine.

Read also: Novartis gets European Commission nod for Pluvicto to treat progressive PSMA-positive metastatic castration-resistant prostate cancer

Ghostine is an experienced business leader with a track record of growing and transforming businesses in competitive industries. He held executive and senior leadership positions at Firmenich and Diageo in a career spanning three decades. He currently serves on two boards of directors; at Danone, where he is a member of the audit committee, and at Four Seasons Hotels & Resorts, where he chairs the remuneration and nomination committee. He holds a master's degree in Business Administration from Saint Joseph University, Lebanon and completed Harvard Business School's Advanced Management Program.

Read also: Novartis division Sandoz to set up Global Capability Centre in Hyderabad